Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, published by TAYLOR & FRANCIS LTD, is a premier academic journal dedicated to advancing our understanding of receptor biology and signal transduction mechanisms. With an ISSN of 1079-9893 and an E-ISSN of 1532-4281, this journal has maintained a reputable standing since its inception in 1980, continually addressing pivotal topics in biochemistry, cell biology, and molecular biology. As evidenced by its 2023 Scopus rankings, which place it in the 64th percentile for Biochemistry and Genetics and Molecular Biology, JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION remains a vital source for cutting-edge research, providing insights that are essential for both academic and practical applications. Although the journal currently offers limited open access options, it stands out in the Q2 and Q3 quartiles of its respective categories, making it an invaluable resource for researchers, professionals, and students aiming to stay abreast of the latest findings and methodologies in receptor and signaling research. The journal's commitment to disseminating high-quality research underscores its significance within the scientific community, fostering innovation and collaboration across disciplines.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

BIOSCIENCE REPORTS, published by Portland Press Ltd, is a prestigious journal dedicated to advancing the fields of biochemistry, biophysics, cell biology, and molecular biology. Founded in 1981, the journal has established itself as a vital resource for researchers and professionals, boasting a significant impact factor and high rankings within its categories, including Q2 in Biochemistry and Q1 in Biophysics as of 2023. The journal’s commitment to high-quality, peer-reviewed research ensures that it remains an influential platform for the dissemination of cutting-edge scientific findings. While it operates under a traditional subscription model, it offers various access options to accommodate the needs of the scientific community. With ongoing publication through 2024, BIOSCIENCE REPORTS continues to play a crucial role in shaping discussions in the life sciences and fostering innovative research in biology.

Current Cancer Therapy Reviews, an esteemed journal published by Bentham Science Publishers Ltd, serves as a critical resource in the fields of cancer research, molecular medicine, and oncology. With an ISSN of 1573-3947 and an E-ISSN of 1875-6301, this journal provides a platform for the rapid dissemination of reviews that articulate the latest advancements and therapeutic strategies in cancer treatment. Although it currently holds a Q4 classification in its respective categories, the journal's commitment to quality scholarship is evident in its engagement with an expansive range of topics impacting cancer care. Operating from the United Arab Emirates since its inception in 2006, it is an essential tool for researchers, clinicians, and students aiming to stay abreast of the evolving landscape of cancer therapy. The journal emphasizes open access to knowledge, fostering a collaborative environment for innovative research. For those looking to deepen their understanding of contemporary cancer therapies, Current Cancer Therapy Reviews is a valuable addition to their academic resources.

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, published by BIOLIFE SAS, is a pivotal platform in the fields of Cancer Research, Endocrinology, Immunology, and Physiology, addressing fundamental aspects of biological regulation and homeostasis. Since its inception in 1987, this journal has consistently contributed to the advancement of knowledge, showcasing innovative research and breakthroughs that are instrumental for professionals, researchers, and students alike. Although categorized in the Q4 quartile across multiple disciplines, the journal offers a unique perspective that encourages exploration into underrepresented areas, underscoring its role in fostering scientific dialogue and collaboration. With ISSN 0393-974X and E-ISSN 1724-6083, the journal remains a crucial resource for those invested in understanding the complexities of homeostatic agents and their implications in health and disease. Based in Silva Marina, Italy, it invites contributions that broaden the horizons of contemporary biomedical research.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Frontiers in Bioscience-Landmark is a prestigious journal published by IMR PRESS that focuses on a diverse array of topics within the fields of biochemistry, genetics, molecular biology, immunology, and microbiology. With the ISSN 2768-6701 and E-ISSN 2768-6698, this journal has carved a significant niche since its inception in 1996, making its mark in contributions to the scientific community all the way through to 2024. Having achieved a respectable Q2 cohort rank in multiple categories, including biochemistry and immunology, it stands out for its impactful research, evidenced by its current Scopus rankings which highlight it as a vital resource for ongoing studies and advancements in the biosciences. Despite not being open access, the journal ensures that readers have access to high-quality research articles that are peer-reviewed and designed to foster academic discourse. The importance of Frontiers in Bioscience-Landmark lies in its commitment to disseminating innovative findings that can significantly enhance our understanding of biological sciences, making it an essential read for researchers, professionals, and students alike.